<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prognostic parameters for treatment outcome in 42 consecutive patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> diagnosed and treated in a single centre between 2000-2010 (mean age: 56.07 years, range: 23-84; 30 females) were evaluated retrospectively/prospectively </plain></SENT>
<SENT sid="1" pm="."><plain>Antecedent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> occurred in 37 patients (88.15%): 28 solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (breast, n=14), nine haematological </plain></SENT>
<SENT sid="2" pm="."><plain>History of previous chemotherapy (CT), radiotherapy (RT) alone and combined CT/RT was present in 42.9%, 6.19% and 30.1% patients, respectively </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">Primary disease</z:e> was active in 11 patients (six relapsed or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancers</z:e>; five <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> preceded t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in 29% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Median latency period from prior CT/RT was 54.62 months (range: 6-243) </plain></SENT>
<SENT sid="6" pm="."><plain>Median WBC count was 27.23 × 10⁹/L, platelet count 62.29 × 10⁹/L, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> level 87.83 g/L, peripheral blood and bone marrow blast percentage 30.7% and 66.7% respectively, serum LDH 1216 U/L </plain></SENT>
<SENT sid="7" pm="."><plain>Aberrant expression of B or T lymphoid markers was registered in seven out of 39 and six out of 39 patients, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Aberrant karyotype was detected in 24 out of 33 (72.7%) of eligible patients: favourable: 15.2%, intermediate: 42.4% and unfavourable: 42.4% </plain></SENT>
<SENT sid="9" pm="."><plain>Eastern Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (ECOG) performance status greater or equal to 2 and Haematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) greater or equal to 3 exhibited 83.3% and 76.2% patients, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Intensive induction CT for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was administered in 24 patients </plain></SENT>
<SENT sid="11" pm="."><plain>The median follow-up and the median overall survival (OS) for the whole cohort were 2 months and 5.94 months (range: 0.5-34), respectively </plain></SENT>
<SENT sid="12" pm="."><plain>In 10 patients (23.8%) achieving complete remission (CR), median disease free survival (DFS) was 11.8 months (range: 4-32) </plain></SENT>
<SENT sid="13" pm="."><plain>Only CD19 expression, pretreatment karyotype, ECOG PS, HCT-CI and activity of <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> had impact on OS (P&lt;0.05) </plain></SENT>
</text></document>